Notice of Annual Meeting

    RNS Number : 5002A
  Research Pharmaceutical SRV, Inc
  01 August 2008
   

    1 August 2008

    ReSearch Pharmaceutical Services, Inc.

    Notice of Annual Meeting

    ReSearch Pharmaceutical Services, Inc. ("RPS" or the "Company"), a leading provider of clinical development outsourcing solutions to the
biopharmaceutical industry, announces that notice of our 2008 annual meeting and proxy statement ("Proxy Statement") has today been mailed
to our stockholders and warrant holders. The annual meeting is to be held at 9.00 a.m. on August 20, 2008 at RPS' office at 520 Virginia
Drive, Fort Washington, Pennsylvania, 19034 ("Annual Meeting").
    The Annual Meeting will, amongst other things, seek stockholders' approval for the cancellation of our common stock from trading on AIM
and warrant holders' approval for the cancellation of our warrants from trading on AIM in anticipation of obtaining a listing on a United
States securities exchange or electronic quotation medium.
    Subject to obtaining our stockholders' and warrant holders' approval at the Annual Meeting, we intend to cancel the common stock and
warrants from trading on AIM on September 1, 2008.  We may choose to delay cancelling our common stock and warrants from trading on AIM, and
if we do not cancel our common stock and warrants from trading on AIM on September 1, 2008, we will request an extension of the date of
cancellation from AIM and publicly announce the new date of cancellation at least 10 business days prior to the new intended date of
cancellation.  In any event, we will not effect the cancellation of our common stock and warrants from trading on AIM on a date later than
December 31, 2008 without obtaining an additional approval from our stockholders and warrant holders.  We reserve the right to forego
cancelling our common stock and warrants from trading on AIM if our Board of Directors determines that remaining admitted to trading on AIM
is in the best interests of our stockholders and warrant holders.
    In the event that the warrant holders do not approve the cancellation of the warrants from trading on AIM but the stockholders do
approve the cancellation of the common stock from trading on AIM, our nominated adviser has indicated that it will resign as of the date our
common stock is cancelled from trading on AIM.  Thereafter, trading of our warrants on AIM will be suspended, and if we do not appoint
another nominated advisor within one month after the suspension of our warrants from trading on AIM (which appointment of a new nominated
advisor we believe is unlikely), the admission of our warrants to trading on AIM will be cancelled.
    Additional information regarding the proposed cancellation of our stock and warrants from trading on AIM can be found in the Proxy
Statement.  This announcement is a summary of the information contained in the Proxy Statement and as such should be read in conjunction
with the full text of the Proxy Statement.
    The Proxy Statement is being filed with the United States Securities and Exchange Commission ("SEC") and is being mailed to our
stockholders and warrant holders today. The Proxy Statement is publicly available on the SEC's website (www.sec.gov).
    Copies of the Proxy Statement will also be available on the Company's website, www.rpsweb.com.
    This announcement is not "soliciting material," is not deemed "filed" with the SEC and is not to be incorporated by reference in any
filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before
or after the date hereof and irrespective of any general incorporation language in any such filing.
    

    For further information please contact:
 ReSearch Pharmaceutical Services, Inc.:                [phone]
 Daniel M. Perlman, Chairman & Chief Executive Officer
 Steven Bell, Chief Financial Officer

 Nominated Adviser and UK Broker:                       [phone]
 Arbuthnot Securities Limited
 James Steel/Richard Tulloch


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCEALPFESEPEFE